OS THERAPIES INCORPORATED Financials
This page shows OS THERAPIES INCORPORATED (OSTX) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 3 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
External financing, not operations, is carrying the company as cash burn repeatedly outruns whatever liquidity each fundraising creates.
FY2024 briefly looked liquid because financing inflow of$12.8M lifted cash to$5.5M and covered a year of losses. By FY2025, operating cash burn reached-$14.2M while cash fell to$270K , showing that the prior cushion was temporary and that the business still relies on new capital rather than internal cash generation.
Cash losses matched accounting losses in FY2025: operating cash flow was
Funding appears equity-linked: shares outstanding climbed from the prior year to 37.1M while financing cash inflow was
Financial Health Signals
Based on FY2025 annual data, averaged across the last 3 years for performance metrics (most-recent year weighted highest). How this score is calculated →
Health score ≠ stock price. This rates the quality of OS THERAPIES INCORPORATED's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
OS THERAPIES INCORPORATED's current ratio of 0.03 is below the typical benchmark, resulting in a score of 0/100. This tight liquidity could limit financial flexibility if cash inflows slow.
OS THERAPIES INCORPORATED passes 1 of 9 financial strength tests. 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).
For every $1 of reported earnings, OS THERAPIES INCORPORATED generates $0.50 in operating cash flow (-$14.2M OCF vs -$28.8M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Key Financial Metrics
Earnings & Revenue
OS THERAPIES INCORPORATED's EBITDA was -$28.3M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 316.1% from the prior year.
OS THERAPIES INCORPORATED reported -$28.8M in net income in fiscal year 2025. This represents a decrease of 223.7% from the prior year.
OS THERAPIES INCORPORATED earned $-0.98 per diluted share (EPS) in fiscal year 2025. This represents an increase of 23.4% from the prior year.
Cash & Balance Sheet
OS THERAPIES INCORPORATED generated -$14.7M in free cash flow in fiscal year 2025, representing cash available after capex.
OS THERAPIES INCORPORATED held $270K in cash against $0 in long-term debt as of fiscal year 2025.
OS THERAPIES INCORPORATED had 37M shares outstanding in fiscal year 2025. This represents an increase of 77.8% from the prior year.
Margins & Returns
Capital Allocation
OS THERAPIES INCORPORATED invested $16.4M in research and development in fiscal year 2025. This represents an increase of 476.3% from the prior year.
OS THERAPIES INCORPORATED invested $466K in capex in fiscal year 2025, funding long-term assets and infrastructure.
OSTX Income Statement
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | $7.4M | N/A | $3.8M+50.2% | $2.5M+90.9% | $1.3M | N/A | $1.2M+205.2% | $397K |
| SG&A Expenses | $2.8M | N/A | $3.1M+33.6% | $2.3M-36.6% | $3.7M | N/A | $1.2M+220.2% | $383K |
| Operating Income | -$10.2M | N/A | -$6.9M-42.2% | -$4.8M+3.2% | -$5.0M | N/A | -$2.4M-212.6% | -$780K |
| Interest Expense | $75K | N/A | N/A | N/A | N/A | N/A | $438K-43.7% | $778K |
| Income Tax | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Income | -$10.4M | N/A | -$6.9M-51.6% | -$4.5M-17.0% | -$3.9M | N/A | -$2.9M-84.6% | -$1.6M |
| EPS (Diluted) | $-0.27 | N/A | $-0.21-10.5% | $-0.19-5.6% | $-0.18 | N/A | $-0.18+30.8% | $-0.26 |
OSTX Balance Sheet
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $7.3M+6.7% | $6.8M-23.6% | $9.0M-13.2% | $10.3M+142.6% | $4.2M-23.3% | $5.5M+180.1% | $2.0M+47.3% | $1.3M |
| Current Assets | $918K+175.6% | $333K-85.7% | $2.3M-34.7% | $3.6M-13.2% | $4.1M-26.0% | $5.5M+180.8% | $2.0M+47.5% | $1.3M |
| Cash & Equivalents | $918K+240.0% | $270K-85.6% | $1.9M-33.0% | $2.8M-5.7% | $3.0M-46.3% | $5.5M+197.8% | $1.9M+1857.4% | $95K |
| Inventory | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $17.1M+43.7% | $11.9M+179.5% | $4.2M+19.3% | $3.6M-57.8% | $8.4M-4.2% | $8.8M+228.0% | $2.7M-90.5% | $28.4M |
| Current Liabilities | $17.0M+44.1% | $11.8M+183.8% | $4.1M+19.9% | $3.5M-2.2% | $3.5M-23.6% | $4.6M+79.0% | $2.6M-90.9% | $28.3M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | -$10.8M-77.6% | -$6.1M-267.6% | $3.6M-26.4% | $4.9M+218.1% | -$4.2M-28.2% | -$3.3M-361.9% | -$707K+97.4% | -$27.1M |
| Retained Earnings | -$77.6M-15.5% | -$67.2M-25.1% | -$53.7M-14.7% | -$46.8M-10.7% | -$42.3M-10.1% | -$38.4M-8.4% | -$35.4M-8.8% | -$32.6M |
OSTX Cash Flow Statement
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$4.6M-22.3% | -$3.7M+20.7% | -$4.7M-99.4% | -$2.4M+31.4% | -$3.4M-44.9% | -$2.4M+29.8% | -$3.4M-284.1% | -$881K |
| Capital Expenditures | N/A | $0 | $0-100.0% | $316K+110.9% | $150K | N/A | N/A | N/A |
| Free Cash Flow | N/A | -$3.7M+20.7% | -$4.7M-75.8% | -$2.7M+25.5% | -$3.6M | N/A | N/A | N/A |
| Investing Cash Flow | N/A | $0 | $0+100.0% | -$293K-68.6% | -$174K | N/A | N/A | N/A |
| Financing Cash Flow | $5.2M+145.4% | $2.1M-43.8% | $3.8M+52.2% | $2.5M+135.9% | $1.1M-82.6% | $6.0M+17.5% | $5.1M+487.7% | $876K |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
OSTX Financial Ratios
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Equity | N/A | N/A | -189.1%-97.4pp | -91.8% | N/A | N/A | N/A | N/A |
| Return on Assets | -142.4% | N/A | -76.8%-32.8pp | -44.0%+47.2pp | -91.2% | N/A | -145.4%-29.4pp | -116.0% |
| Current Ratio | 0.05+0.0 | 0.03-0.5 | 0.56-0.5 | 1.03-0.1 | 1.16-0.0 | 1.20+0.4 | 0.76+0.7 | 0.05 |
| Debt-to-Equity | -1.58+0.4 | -1.95-3.1 | 1.17+0.4 | 0.72+2.7 | -2.02+0.7 | -2.70+1.1 | -3.80-2.7 | -1.05 |
| FCF Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Note: Shareholder equity is negative (-$6.1M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Note: The current ratio is below 1.0 (0.03), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Similar Companies
Frequently Asked Questions
Is OS THERAPIES INCORPORATED profitable?
No, OS THERAPIES INCORPORATED (OSTX) reported a net income of -$28.8M in fiscal year 2025.
What is OS THERAPIES INCORPORATED's EBITDA?
OS THERAPIES INCORPORATED (OSTX) had EBITDA of -$28.3M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is OS THERAPIES INCORPORATED's free cash flow?
OS THERAPIES INCORPORATED (OSTX) generated -$14.7M in free cash flow during fiscal year 2025. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is OS THERAPIES INCORPORATED's operating cash flow?
OS THERAPIES INCORPORATED (OSTX) generated -$14.2M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are OS THERAPIES INCORPORATED's total assets?
OS THERAPIES INCORPORATED (OSTX) had $6.8M in total assets as of fiscal year 2025, including both current and long-term assets.
What are OS THERAPIES INCORPORATED's capital expenditures?
OS THERAPIES INCORPORATED (OSTX) invested $466K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does OS THERAPIES INCORPORATED spend on research and development?
OS THERAPIES INCORPORATED (OSTX) invested $16.4M in research and development during fiscal year 2025.
What is OS THERAPIES INCORPORATED's current ratio?
OS THERAPIES INCORPORATED (OSTX) had a current ratio of 0.03 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.
What is OS THERAPIES INCORPORATED's debt-to-equity ratio?
OS THERAPIES INCORPORATED (OSTX) had a debt-to-equity ratio of -1.95 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is OS THERAPIES INCORPORATED's return on assets (ROA)?
OS THERAPIES INCORPORATED (OSTX) had a return on assets of -420.4% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is OS THERAPIES INCORPORATED's cash runway?
Based on fiscal year 2025 data, OS THERAPIES INCORPORATED (OSTX) had $270K in cash against an annual operating cash burn of $14.2M. This gives an estimated cash runway of approximately 0 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
Why is OS THERAPIES INCORPORATED's debt-to-equity ratio negative or unusual?
OS THERAPIES INCORPORATED (OSTX) has negative shareholder equity of -$6.1M as of fiscal year 2025, which causes the debt-to-equity ratio to appear negative or not meaningful. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.
What is OS THERAPIES INCORPORATED's Piotroski F-Score?
OS THERAPIES INCORPORATED (OSTX) has a Piotroski F-Score of 1 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are OS THERAPIES INCORPORATED's earnings high quality?
OS THERAPIES INCORPORATED (OSTX) has an earnings quality ratio of 0.50x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is OS THERAPIES INCORPORATED?
OS THERAPIES INCORPORATED (OSTX) scores 0 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.